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Pan PantziarkaAbstract
Li Fraumeni Syndrome (LFS) is a rare autosomal dominant hereditary cancer syndrome characterized by germline
mutations in the TP53 tumour suppressor gene. Sufferers are prone to early onset cancers, particularly sarcomas,
adrenocortical carcinoma and breast cancer. Cells from LFS sufferers are known to exhibit telomere dysfunction,
genomic instability and spontaneous immortalisation. It is hypothesized that these facets of the LFS host are
evidence that the host environment is “primed” for carcinogenesis over and above the lack of p53 tumour
suppressor function. Further, it is hypothesized that the host presents an ideal environment for "two compartment
tumour metabolism" to take place. Evidence from recent studies supports this new view of LFS and suggests that
disrupting certain features of the host environment may markedly reduce the incidence of cancer in LFS sufferers.
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Li Fraumeni Syndrome (LFS) is a rare autosomal domin-
ant hereditary cancer syndrome characterized by germline
mutations in the TP53 tumour suppressor gene. The syn-
drome is associated with a range of cancers, particularly
sarcomas, gliomas, adrenocortical and breast carcinomas
as well as other malignancies, particularly during child-
hood and early adulthood [1,2]. Among women with LFS,
the most common disease is breast cancer, with a 49% risk
of developing the disease by age 60 [3]. Overall the life-
time risk of cancer is estimated at 52% by age 40 years
and 80% by age 50 years and for women the life-time risk
has been estimated at 100% in one study [2,4,5].
The “two compartment tumour metabolism” hypothe-
sis is a new paradigm that describes a metabolic shuttle
between autophagic cells in the tumour stroma and
tumour cells [6,7]. The hypothesis suggests that cancer
cells induce oxidative stress in the stroma by secreting
hydrogen peroxide in surrounding tissues. Cancer-
associated fibroblasts respond to this environmental
challenge by activation and entry into an autophagic
state and undergo mitophagy, mitochondrial dysfunction
and a shift of metabolism towards aerobic glycolysis.
This metabolic shift in cancer-associated fibroblastsCorrespondence: anticancer.org.uk@gmail.com
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reproduction in any medium, provided the orresults in the production of high energy by-products
such as l-lactate, ketones, glutamine and other mito-
chondrial fuels that the tumour cells require to drive
growth [8,9].
At the heart of this relationship between tumour cells
and the surrounding stromal tissues is the autophagic
response to oxidative stress [10]. Recent evidence points
to a relationship between cellular senescence and auto-
phagy, suggesting that they are part of the same
“autophagy-senescence transition (AST)”, and that they
both promote the anabolic growth of cancer cells. It also
links aging and cancer in a radically new way, suggesting
that cancer is a disease of “accelerated host aging” in the
tumour stroma [6,11].Presentation of the hypothesis
In this paper we present the novel hypothesis that many
of the features of the "two compartment" model of
cancer, including accelerated host aging, are present in
the non-cancerous LFS host, and that people with LFS
are therefore "primed" for cancer development over and
above a simple loss of p53 tumour suppressor function.
Evidence for the hypothesis is reviewed, and the clinical
implications discussed.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Pantziarka Cancer Cell International 2013, 13:35 Page 2 of 6
http://www.cancerci.com/content/13/1/35Telomeres, senescence and immortalisation
Telomeres are regions of nucleotide sequences that cap
the ends of each chromosome and serve to protect the
chromosome from recombination or degradation. Succes-
sive cell division leads to a shortening of telomere lengths,
a process that can lead to chromosomal instability and
which is associated both with aging and the pathology of a
number of diseases, including cancer. In many respects
telomere length can be seen as an indicator of biological
aging independent of chronological age [12-14]. Crucially,
shortened telomeres activate p53 to trigger a DNA damage
response that can lead to senescence or apoptosis [15].
Clinical evidence exists that LFS patients have shorter
telomeres than age-matched non-LFS individuals [16].
In other studies, children with LFS were shown to have
mean telomere length shorter than unaffected parents or
siblings [17]. These findings are in line with evidence
from LFS fibroblast cell lines derived from patients and
in p53−/− and p53+/− knockout mice [18]. In an
analysis performed in 2007, shorter telomere length was
associated with a younger age of cancer onset in LFS
patients, and there was convincing evidence of increased
telomere attrition in succeeding generations [19].
Analysis of non-malignant fibroblasts and other cells
derived from LFS patients has shown that they display
unusual patterns of senescence and that some of them are
able to undergo spontaneous immortalisation in vitro.
Where control fibroblasts from skin biopsies undergo
senescence in the normal way in cultures, some of the
fibroblasts from a number of LFS patients enter a long
period of growth slowdown and replicative senescence
during which they alter morphology, suffer chromosomal
damage, including aneuploidy and telomeric association,
followed by escape from senescence and the resumption
of cell division and replication.
It should be noted that spontaneous immortalisation
of human fibroblasts almost never occurs in cultures
from non-LFS patients [20,21]. Furthermore, immorta-
lized LFS fibroblasts are not directly tumorigenic when
transplanted into nude mice. So while this immortalisa-
tion of cells is a necessary condition of malignant trans-
formation it is not a sufficient condition [20].Figure 1 LFS cells with shorter telomere lengths and lacking function
moving into premature senescence, immortalisation and malignant trEscape from senescence is often associated with
the over-expression of telomerase reverse transcriptase
(TERT), the enzyme complex that re-synthesizes the telo-
mere ‘caps’ at the end of the chromosome. Increased
expression of telomerase is common to many cancers,
conversely this enzyme is absent from non-transformed
cells [22]. Some tissues may be more susceptible to this
process than others, as shown in the work of Shay et al.
who demonstrated that breast epithelial cells immortalised
more frequently than fibroblasts in cultures from an LFS
patient [23]. Comparison of the telomerase staining for
the different cell types showed significantly higher levels
in the breast epithelial cells than in the stromal
fibroblasts.
This cell-type specific difference is important in that it
is a possible factor in the patterns of cancer incidence in
LFS. Breast cancer in LFS affected women is the most
common form of the disease, occurring in about 50% of
female TP53 mutation carriers (although risk to those
that survive to 50 years may be in excess of 70%). Site
specific escape from senescence might also explain the
prevalence of bone and soft tissue sarcomas, adrenocor-
tical carcinoma and other forms of cancer that are rare
in the general population but common in LFS.
This differential rate of immortalisation and senes-
cence also leads to a situation where small populations
of immortalized epithelial cells, subject to mutation and
chromosomal change, are surrounded by populations of
cells with reduced telomere lengths and already in senes-
cence or becoming senescent in response to oxidative
stress (Figure 1). In the context of LFS and the “two
compartment” model the stage is set for these immor-
talized epithelial cells to undergo malignant trans-
formation and to activate the fibroblastic cells in the
stroma [24].
TP53, Autophagy and oxidative stress
p53 also plays a role in cellular homeostasis, metabolism
and in how cells respond to nutrient deficiency, hypoxia
and other stresses. p53 can up regulate oxidative phos-
phorylation (OXPHOS) by inducing the synthesis of cyto-
chrome c oxidase (SCO2) and down-regulate glycolysisal p53 respond to cellular stresses, including oxidative stress, by
ansformation.
Table 1 Characteristics of accelerated host aging in





Senescent Fibroblasts ✓ ✓
High Oxidative Stress ✓ ✓
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(TIGAR) [25-27].
Activated cancer associated fibroblasts undergo transi-
tion to an autophagic state according to the “two com-
partment” hypothesis. Mechanistically, one of the drivers
of this transition is an increased rate of oxidative stress
due to secreted reactive oxygen species from adjacent
cancer cells [28]. There is increasing evidence that p53
is an important regulator of the shift to autophagy. The
picture is complex and it appears that p53 may have a
dual effect on autophagy, acting as a promoter or inhibi-
tor depending on its localization in the cell [29,30].
However, Tasdemir et al. have shown that inhibition,
knockout or knock-down of p53 acts as a potent inducer
of autophagy in a range of cell types, including fibro-
blasts [31]. Lisanti and colleagues specifically link this
increased oxidative stress with accelerated host aging in
the tumour microenvironment [11,28].
Analysis of the redox parameters in blood samples of
healthy LFS patients compared to non-carriers of TP53
mutations found that the LFS mutation carriers had
significantly increased indicators of oxidative stress,
including a four-fold increase in plasma malondialdehyde
levels, indicating increased lipid peroxidation [32]. This is,
therefore, further evidence of the priming of the LFS host
with the pre-conditions for cancer initiation and progres-
sion according to the “two compartment” theory.
The role of Cav-1
Caveolin-1 (cav-1) is the principal structural component
of caveolae, plasma membrane invaginations that partici-
pate in diverse cellular activities and are abundant in many
cell types. Cav-1 regulates critical cell functions including
proliferation, apoptosis, cell differentiation, and transcy-
tosis via diverse signalling pathways. Cav-1 knock-out
(KO) mice are an established animal model of premature
aging, exhibiting shorter life-span, increased glucose toler-
ance, insulin resistance and other age-related conditions.
Additionally cav-1 KO mice show increased oxidative
stress and mitochondrial dysfunction, which are also
markers of accelerated host aging [33].
A key hallmark of Lisanti’s “two compartment” theory
is a loss of stromal cav-1 and a corresponding up-
regulation of cav-1 in tumour cells (i.e. the effects of
cav-1 are compartment-specific) [34]. Loss of stromal
cav-1 expression is a key indicator of the effect of
immortalized epithelial cells on adjacent fibroblasts
[35,36].
A recent study by Sherif and Sultan analysed cav-1 ex-
pression in non-cancerous LFS fibroblasts and reported
that affected family members showed an 88% down-
regulation of cav-1 compared to non-affected family
members [37]. This new finding is directly as predicted
by our hypothesis and confirms that another key featureof the “two compartment” model, (and one that is also
related to characteristics of accelerated host aging), is
present in the non-malignant LFS host environment.
Summary
We have outlined a number of important characteristics
of the “two compartment” model and have shown how
these exist in the non-cancerous LFS host, as shown in
Table 1. Furthermore, we have presented evidence that
these characteristics are closely associated with the ac-
celerated host aging described in the “two compartment”
model of cancer.
Testing the hypothesis
Our hypothesis predicts that disrupting the “priming” of
the host environment will reduce cancer initiation and
progression in LFS sufferers and can be tested by under-
taking specific interventions. Specifically, there are three
possible targets:
 inhibiting senescence in stromal cells
 inducing autophagy in malignant cells/inhibiting
autophagy in stromal cells
 interrupting the metabolic shuttle between stromal
fibroblasts and tumour cells
These three targets alter the host environment in such
a way as to disrupt the “priming” towards the two com-
partment model, and in theory would markedly reduce
the risk of developing cancer in LFS sufferers. A number
of important results already suggest that these mecha-
nisms can make a significant impact on cancer risk for
LFS sufferers.
Komarova and colleagues showed that the mTOR
inhibitor rapamycin, which is known to inhibit cellular
senescence, increased lifespan and decreased the inci-
dence of spontaneous tumours in p53 +/− mice [38].
The effect was stronger when started early in life, sug-
gestive of a systemic effect in the host rather than in
direct anti-tumour activity. According to our hypothesis
rapamycin will decrease the number of cells which enter
senescence and hence reduce the number which escape
from this state and achieve immortalisation, in turn
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transformation. In other words, decreasing senescence
will interrupt the progression shown in Figure 1. Simi-
larly, inhibiting senescence will also stop stromal cells
responding to the oxidative stress produced by esta-
blished tumours by moving into an autophagic state
wherein they can “feed” high-energy food to the coupled
tumour cells. Thus, retarding the onset of senescence
has compartment-specific effects which interrupt the
metabolic shuttle between tumour and stroma.
While inhibiting senescence is one possible means of
interrupting this metabolic shuttle, another possible
mechanism is to induce autophagy in the tumour com-
partment. The “two compartment” model shows that
activated stromal fibroblasts respond to the oxidative
stress generated by tumours by becoming autophagic and
switching metabolism to aerobic glycolysis, which gener-
ates high-energy fuels that can drive the growth of tumour
cells [6,8]. However, inducing autophagy in the tumour
compartment disrupts the metabolic shuttle as the
tumour cells, depending on mitochondrial oxidative phos-
phorylation, are no longer able to feed on the supply of
nutrients from the stroma. Alternatively, inhibiting au-
tophagy in the stroma will deliver the same outcome. One
possible mechanism to achieve this is through the use of
the autophagy-inhibitor chloroquine, which is currently
being used in a number of clinical trials in combination
with a range of chemotherapeutic agents.
Finally, the hypothesis suggests that carcinogenesis
and disease progression in LFS is sensitive to the
metabolic state of cancer associated fibroblasts and adja-
cent tumour cells. Mutant p53 is stabilised by increased
glucose supply, and high levels of mutant p53 act as an
inhibitor of autophagy in cancer cells [39]. Reducing
glucose supply, therefore, will reduce the stabilisation of
mutant p53. It will also decrease the nutrient supply to
the stromal fibroblasts which in turn reduces the supply
of fuels to “feed” the tumour cells.
Another prediction of the hypothesis is, therefore, that
cancer incidence in LFS can be reduced by restriction of
the supply of glucose. Options for altering the availability
of glucose include dietetic alterations or pharmacological
interventions. Supporting evidence for a metabolic in-
fluence in LFS carcinogenesis is provided by work on
p53 +/− mice, which showed that calorie restriction in
adult animals delayed the development of cancer [40].
Chief among the pharmacological interventions is the
use of the anti-diabetic drug metformin, already in
clinical trials in combination with standard chemothe-
rapy agents. Metformin is known to target many of the
pathways affected by dietary caloric restriction, including
AMPK, mTOR and IGFR [41]. In the context of the LFS
phenotype it would have dual effects. First it acts to
restrict the supply of glucose, through the inhibition ofhepatic glucose production, to activated stromal cells.
Secondly it can act to block mitochondrial oxidative
phosphorylation in the tumour cells, hence acting to
starve cancer cells through two distinct pathways. There
is also some evidence that metformin can selectively
induce apoptosis in p53-deficient cells under-going
nutrient stress, which is of significant interest [42].
Implications of the hypothesis
In LFS cancer initiation is more likely than in the gen-
eral population and may be triggered by the genetic
instability that results from shortened telomere lengths,
which may be exacerbated by high basal levels of oxida-
tive stress, and by a lack of functional p53. Once cancer
is initiated the host environment is already in a state
where stromal fibroblasts respond to tumour cells by
becoming activated and moving into a state of auto-
phagy, mitophagy and switching metabolism to aerobic
glycolysis, thereby feeding the tumour cells with the high
energy by-products of this form of metabolism. In short,
cancer in LFS patients rapidly moves to a state of “two
compartment” tumour metabolism.
To date the common understanding has been that LFS
patients are at greater risk of developing malignancies
because of the accumulation of secondary mutations
over and above the mutated TP53. However, the "two
compartment tumour metabolism" hypothesis and the
additional data outlined above suggest that p53 loss in
the stroma accelerates the process of their recruitment by
immortalized epithelial cells to promote tumour forma-
tion. Thus malignancy in LFS is associated with cellular
senescence in stromal cells in response to increased oxida-
tive stress from epithelial cells, a process which may be
regarded as a form of accelerated host aging [11].
The hypothesis outlined here is consistent with the
patterns of cancer incidence in LFS affected families, for
example, the tendency to early onset cancers of specific
tissues, such as breast cancer or soft tissue or bone
sarcomas, rather than an across the board tendency to
all forms of cancer. In particular, it may shed light on
the paradox that LFS patients do not show an increased
incidence of cancers related to tobacco, environmental
toxins or occupation, as would be expected if damaged
DNA repair mechanisms were the primary outcome
from loss of TP53 function [43]. It may also explain the
higher incidence of cancer before the age of 40, as those
individuals with the “more aged” LFS phenotype (shorter
telomeres, fibroblastic cells more likely to move into
senescence and autophagy, higher levels of basal oxida-
tive stress, greater loss of cav-1) develop cancer at a
younger age than those with a more normal telomeric
profile (a “less aged” phenotype).
This shift in emphasis from a focus on accumulated
DNA damage to cell-type interactions and accelerated
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Currently there are no cancer prevention strategies in
place for LFS sufferers. Newly diagnosed patients are
subject to varying levels of surveillance but are offered
no practical steps to reduce the risk of developing malig-
nancies other than bilateral risk reducing mastectomy in
women. This imposes high levels of stress on patients
and their families, particularly for parents of LFS
children and in families with extensive cancer histories.
The hypothesis outlined here opens the door to active
chemo-preventative strategies in terms of autophagy
inhibition, steps to reduce oxidative stress and so on.
Drugs such as the anti-diabetic drug metformin, the
autophagy inhibitor chloroquine and other agents with
low toxicity, including anti-oxidants, may also be worthy
of further investigation in LFS families.
Research is also warranted to ascertain whether shorter
telomere length, reduced cav-1 expression or increased
oxidative stress have prognostic significance in LFS.
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